

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**APPLICATION NUMBER: NDA 20998/S007**

**CHEMISTRY REVIEW(S)**

**DIVISION OF ONCOLOGY DRUG PRODUCTS**  
**Original NDA Review of Chemistry, Manufacturing, and Controls**

<b>NDA #:</b> 21-156	<b>CHEMISTRY REVIEW #:</b>	<b>1</b>	<b>REVIEW DATE:</b> December 20, 1999
<b>SUBMISSION TYPE</b>	<b>DOC. DATE</b>	<b>CDER DATE</b>	
Original	June 24, 1999	June 25, 1999	
Amendment	December 16, 1999	December 16, 1999	

**NAME & ADDRESS OF APPLICANT:** G.D. Searle & Co., 4901 Searle Parkway, Skokie, IL 60077

**DRUG PRODUCT NAME:**

Proprietary:	Celebrex™ Capsules
Nonproprietary/USAN:	Celecoxib
Chem. Type/Ther. Class:	IP

**PHARMACOL. CATEGORY/INDICATION:** For the reduction and regression of adenomatous colorectal polyps in Familial Adenomatous Polyposis patients

**DOSAGE FORM:**

Oral Capsule

**STRENGTHS:**

200mg/capsule

**ROUTE OF ADMINISTRATION:**

Oral

**DISPENSED:**

☒ Rx ☐ OTC


**CHEMICAL NAME. STRUCTURAL FORMULA. MOLECULAR FORMULA(M.F.).  
MOLECULAR WEIGHT(M.W.):**

CAS Name: 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide

M.F.: C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S

M.W.: 381.38

**CONSULTS:** Not applicable.



**REMARKS/COMMENTS:**

NDA 21-156 efficacy supplement to NDA 20-998 is submitted. The cross-referenced NDA 20-988 was approved on 12/31/98 for the acute or chronic use in the treatment of the signs and symptoms of osteoarthritis and rheumatoid arthritis in adults. Approved strengths are 100mg and 200mg per capsule.

**CONCLUSIONS & RECOMMENDATIONS:**

No CMC review is required because of efficacy supplement except an environmental assessment. The applicant requested a categorical exclusion from the preparation of the environmental assessment under the provisions of 21CFR 25.31(a) concerning this NDA 21-156. For justification, it is stated that the total planned production of celecoxib is expected to remain within the marketing projections made in the original environmental assessment in the NDA 20-988 application. No increase in the production of celecoxib is expected due to approval of this efficacy supplement. The exemption request for the preparation of the environmental assessment is granted. Adequate.

cc:

Orig. NDA 21-156

HFD-150/Division File

HFD-150/PZimmerman

HFD-150/SKim

HFD-150/RWood

R/D Init. by: RHWood 12-20-99

filename: N21156.org

/S/  
Sung K. Kim, Ph.D.,  
Review Chemist, HFD-150